What is Melorheostosis?

Cause and symptoms
Genetics
Epidemiology
Case report
Diagnosis and treatment
References
Further reading


Melorheostosis, also known as Leri disease, is a rare non-genetic sclerotic bone disease. The name melorheostosis is made from the combination of three Greek words: melos (limb), rhein (flowing), and ostosis (bone formation). It is a chronic condition marked by dense cortical sclerotic bone and adjacent soft tissue structure in a sclerotomal distribution.

Image Credit: Video_Stock _Production/Shutterstock.com

Image Credit: Video_Stock _Production/Shutterstock.com

Mutations in the MAP2K1 gene are believed to be responsible for almost half of all instances of melorheostosis. This condition is not hereditary and cannot be passed down to offspring. It is caused by somatic mutations in bone cells that develop during a person's life.

It was first described in 1922 by Leri and Joanny, and until now, more than 400 cases have been reported in the literature. Melorheostosis is more frequent in the appendicular skeleton than in the axial skeleton and usually manifests as lower limb malformation. A combination of clinical and radiological features is used to make the diagnosis

Cause and symptoms

Isolated Melorheostosis (with no other associated disorders) is more common in those who have no family history of the ailment. Approximately half of all isolated Melorheostosis cases are caused by acquired, somatic genetic alterations in the MAP2K1 gene. These genetic mutations are not inherited from one's parents and occur randomly throughout one's life. The etiology of the remaining cases is unknown.

Although some cases of melorheostosis are identified by chance before the development of signs or symptoms, pain, stiffness, and limitation of joint motion or deformity are frequently the first symptoms that drive patients to seek medical attention.

The onset is gradual, and symptoms range from none to severe deformity due to contracture. Cranial nerve paralysis, ectopic ossification in muscle tissue, increased bone mineral density, and hyperostosis are frequently observed. Skeletal muscle atrophy and asymmetry in the lower and upper limbs are also frequent.

Osseous involvement can be monostotic or polyostotic, or monomelic, but it is usually confined to one limb. However, it can also be bilateral. The most common form of this rare disease is the monomelic variety. When polyostotic, it generally crosses joint gaps while remaining sclerotomal. Limb length disparity can occur as a result of asymmetric early epiphyse fusion.

Early onset and inclusion of numerous limbs may suggest a worse outcome in terms of complications. Melorheostosis is characterized by uneven thickening of cortical bone, which appears in classic cases like "melted wax flowing down a candle."

Genetics

The MAP2K1 gene codes for a protein known as a MEK1 protein kinase. This protein is found in a variety of cells, including bone cells. It is a component of the RAS/MAPK signaling pathway. This signaling system regulates cell proliferation, differentiation, and migration. RAS/MAPK signaling is required for proper development, including bone formation.

The mutations result in the creation of an overactive version of the MEK1 protein kinase, which enhances RAS/MAPK signaling in bone tissue. Increased signaling affects the regulation of bone cell proliferation, allowing for aberrant bone growth.

Image Credit: Billion Photos/Shutterstock.com

Image Credit: Billion Photos/Shutterstock.com

According to research, elevated RAS/MAPK signaling also promotes excessive bone remodeling, a normal process in which old bone is broken down and new bone is formed to replace it. Alterations in bone development and turnover cause bone abnormalities associated with melorheostosis.

Epidemiology

Melorheostosis is most common in youth or early adulthood, with an incidence of 0.9 per million. Although alterations develop in early childhood, the age at presentation is frequently later, and the disease frequently remains undiagnosed until late adolescence or early adulthood. Only about half of the time is the diagnosis made before age 20.

Case report

Kumar et al. described a 35-year-old lady complaining of left leg pain, minor edema, and limited knee movement. Her limb pain had been present for the past 20 years. The edema and restriction of joint movement progressed progressively. There was no relevant family history or trauma to speak of. On inspection, there was no tender bony hearing, edema, hyperpigmentation, or restriction of knee movement. Plain radiographs revealed widespread, thick, undulating, or irregular cortical hyperostosis that resembled candle wax and ran the length of the bone. The patient was given Pamidronate as well as an analgesic. Physiotherapy for the deformity began.

Diagnosis and treatment

Melorheostosis is difficult to diagnose because it can present with clinical and radiologic symptoms comparable to tumors and other sclerosing bone disorders, such as intramedullary osteosclerosis and osteopoikilosis. Although the typical radiographic "dripping candle wax" appearance aids in diagnosis, it is not a ubiquitous finding in melorheostosis patients. As a result, the absence of a thorough pathologic description and a confirmation test can make the diagnosis subjective.

Melorheostosis morbidity appears to be mostly caused by discomfort, contractures, limits of joint motion, limb length disparities, and osseous abnormalities. In the past, tendon lengthening, excision of soft tissue masses, the release of joint contractures, and osteotomies were the primary treatment choices, but recurrence is prevalent. There are no clinical trials or recommendations to guide medical treatment for painful hyperostosis. Targeting the cause of discomfort in melorheostosis may aid in therapy. Bisphosphonates and other antiresorptive medicines are often utilized for pain management. Typically, a multimodal approach is used, with coordinated care emphasizing pain control and functional restrictions.

References

  • Fick, C. N., Fratzl-Zelman, N., Roschger, P., Klaushofer, K., Jha, S., Marini, J. C., & Bhattacharyya, T. (2019). Melorheostosis: A Clinical, Pathologic, and Radiologic Case Series. The American journal of surgical pathology, 43(11), 1554–1559. https://doi.org/10.1097/PAS.0000000000001310
  • Kotwal, Anupam, and Bart L Clarke. "Melorheostosis: a Rare Sclerosing Bone Dysplasia." Current osteoporosis reports vol. 15,4 (2017): 335-342. doi:10.1007/s11914-017-0375-y
  • Smith, Gabriel C et al. "Melorheostosis: A Retrospective Clinical Analysis of 24 Patients at the Mayo Clinic." PM & R: the journal of injury, function, and rehabilitation vol. 9,3 (2017): 283-288. doi:10.1016/j.pmrj.2016.07.530
  • Kumar, R., Sankhala, S. S., & Bijarnia, I. (2014). Melorheostosis - Case Report of Rare Disease. Journal of orthopaedic case reports, 4(2), 25–27. 
  • Melorheostosis. [Online] MedlinePlus. Available at: https://medlineplus.gov/genetics/condition/melorheostosis/
  • Melorheostosis. [Online] NIH-GARD. Available at: https://rarediseases.info.nih.gov/diseases/9474/melorheostosis
  • Melorheostosis. [Online] Radiopaedia. Available at: https://radiopaedia.org/articles/melorheostosis-1

Last Updated: May 17, 2023

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    S. A., Syed. (2023, May 17). What is Melorheostosis?. News-Medical. Retrieved on December 10, 2024 from https://www.news-medical.net/health/What-is-Melorheostosis.aspx.

  • MLA

    S. A., Syed. "What is Melorheostosis?". News-Medical. 10 December 2024. <https://www.news-medical.net/health/What-is-Melorheostosis.aspx>.

  • Chicago

    S. A., Syed. "What is Melorheostosis?". News-Medical. https://www.news-medical.net/health/What-is-Melorheostosis.aspx. (accessed December 10, 2024).

  • Harvard

    S. A., Syed. 2023. What is Melorheostosis?. News-Medical, viewed 10 December 2024, https://www.news-medical.net/health/What-is-Melorheostosis.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Global end-to-end solutions partner to life sciences organisations, AscellaHealth, joins Manchester Science Park